1. International Network of Agencies for Health Technology Assessment, 
2. Drummond, et al.: Int. J. Technol. Ass. Health Care 24(3), 244– 258 (2008)
3. Australia Commonwealth Department of Health, Housing and Community Services. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Commonwealth Department, Canberra (1992)
4. Detsky, A.S.: Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada. Pharmacoeconomics 3, 345–361 (1993)
5. Graf von der Schulenburg, J.M., Greiner, W., Jost, F., Klusen, N., Kubin, M., Leidl, R., Mittendorf, T., Rebscher, H., Schoeffski, O., Vauth, C., Volmer, T., Wahler, S., Wasem, J., Weber, C., the Hanover Consensus Group: German recommendations on health economic evaluation: third and updated version of the Hanover consensus. Value Health 11(4), 539–544 (2008)
6. Mauskopf, J.A., Sullivan, S.D., Annemans, L., Caro, J., Mullins, C.D., Nuijten, M., Orlewska, E., Watkins, J., Trueman, P.: Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices—budget impact analysis. Value Health 10(5), 336–347 (2007)
7. Weinstein, M.C., Fineberg, H.V.: Clinical Decision Analysis, pp. 228–265. Saunders, Philadelphia (1980)
8. Nuijten, M.J., Rutten, F.: Combining a budgetary-impact analysis and a cost-effectiveness analysis using decision-analytic modelling techniques. Pharmacoeconomics 20(12), 855–867 (2002)
9. Critchfield, G., Willard, K., Conelly, D.: Probabilistic sensitivity analysis methods for general decision models. Comput. Biomed. Res. 19, 254–265 (1986)
10. Doubilet, P., Begg, C.B., Weinstein, M.C., et al.: Probabilistic sensitivity analysis using Monte Carlo simulation. Med. Decis. Mak. 5, 157–177 (1985)